These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Hu J; Liu J; Corey DR Chem Biol; 2010 Nov; 17(11):1183-8. PubMed ID: 21095568 [TBL] [Abstract][Full Text] [Related]
6. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309 [TBL] [Abstract][Full Text] [Related]
8. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Hu J; Matsui M; Corey DR Ann N Y Acad Sci; 2009 Sep; 1175():24-31. PubMed ID: 19796074 [TBL] [Abstract][Full Text] [Related]
9. Haplotype background, repeat length evolution, and Huntington's disease. Falush D Am J Hum Genet; 2009 Dec; 85(6):939-42. PubMed ID: 20004772 [No Abstract] [Full Text] [Related]
10. Progress and challenges in RNA interference therapy for Huntington disease. Harper SQ Arch Neurol; 2009 Aug; 66(8):933-8. PubMed ID: 19667213 [TBL] [Abstract][Full Text] [Related]
12. Delivering a disease-modifying treatment for Huntington's disease. Godinho BM; Malhotra M; O'Driscoll CM; Cryan JF Drug Discov Today; 2015 Jan; 20(1):50-64. PubMed ID: 25256777 [TBL] [Abstract][Full Text] [Related]
13. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740 [TBL] [Abstract][Full Text] [Related]
14. An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases. Fiszer A; Olejniczak M; Switonski PM; Wroblewska JP; Wisniewska-Kruk J; Mykowska A; Krzyzosiak WJ BMC Mol Biol; 2012 Mar; 13():6. PubMed ID: 22397573 [TBL] [Abstract][Full Text] [Related]
15. Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models. Conroy F; Miller R; Alterman JF; Hassler MR; Echeverria D; Godinho BMDC; Knox EG; Sapp E; Sousa J; Yamada K; Mahmood F; Boudi A; Kegel-Gleason K; DiFiglia M; Aronin N; Khvorova A; Pfister EL Nat Commun; 2022 Oct; 13(1):5802. PubMed ID: 36192390 [TBL] [Abstract][Full Text] [Related]
16. Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. Jimenez-Sanchez M; Licitra F; Underwood BR; Rubinsztein DC Cold Spring Harb Perspect Med; 2017 Jul; 7(7):. PubMed ID: 27940602 [TBL] [Abstract][Full Text] [Related]
17. Neurobiology of Huntington's disease. Sharp AH; Ross CA Neurobiol Dis; 1996 Feb; 3(1):3-15. PubMed ID: 9173909 [No Abstract] [Full Text] [Related]
18. The enigma of Huntington's disease. Cattaneo E; Rigamonti D; Zuccato C Sci Am; 2002 Dec; 287(6):92-7. PubMed ID: 12469651 [No Abstract] [Full Text] [Related]
19. Huntington's disease. In reverse gear. Bates G Nature; 2000 Apr; 404(6781):944-5. PubMed ID: 10801109 [No Abstract] [Full Text] [Related]
20. Lentiviral-mediated gene transfer of siRNAs for the treatment of Huntington's disease. Cambon K; Déglon N Methods Mol Biol; 2013; 1010():95-109. PubMed ID: 23754221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]